Shaanxi Panlong Pharmaceutical (002864.SZ) released its performance for the first three quarters, with a net income of 89.5717 million yuan, a year-on-year increase of 6.50%.

Shaanxi Panlong Pharmaceutical (002864.SZ) released the third quarter report for 2024, achieving revenue...

Zhitong Finance APP News, Shaanxi Panlong Pharmaceutical (002864.SZ) released the third quarter report for 2024, achieving revenue of 0.717 billion yuan, a year-on-year growth of 0.10%. The net income attributable to shareholders of the listed company was 89.5717 million yuan, a year-on-year increase of 6.50%. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 80.5921 million yuan, a year-on-year decrease of 5.80%.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

盘龙药业(002864.SZ)发布前三季度业绩，净利润8957.17万元，同比增长6.50%

Shaanxi Panlong Pharmaceutical (002864.SZ) released its performance for the first three quarters, with a net income of 89.5717 million yuan, a year-on-year increase of 6.50%.

Risk Disclaimer

Statement